Can adding radiation to osimertinib keep lung cancer in check?

NCT ID NCT05089916

Ongoing Disease control Sponsor: AIO-Studien-gGmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether it is safe and effective to continue the targeted therapy osimertinib while also giving radiation to areas where lung cancer has started to grow again. The study includes 42 adults with EGFR-positive non-small cell lung cancer who are already on osimertinib. Researchers will monitor side effects, cancer progression, and quality of life during and after the combined treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib (Tagrisso) and radiotherapy
What this could lead to: If successful, this could show that combining osimertinib with targeted radiation is safe and helps control cancer growth longer in patients with limited progression.
What could go wrong: This is a small, early-phase study with only 42 participants, so results may not apply broadly. There is a risk of serious side effects like lung inflammation or heart problems from the combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR POSITIVE NON-SMALL CELL LUNG CANCER NSCLC OLIGOPROGRESSION

Contacts and locations

Locations

LMU Klinikum der Universität München

München, 80336, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.